Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Ohr presents update on clinical development of OHR/AVR-118 for cachexia

Nov. 27, 2009

Merck & Co. claims novel hypoxia-inducible factor prolyl hydroxylase inhibitors

Nov. 27, 2009

FDA reviews preliminary data from SCOUT safety study of Meridia

Nov. 26, 2009

Novel dipeptidyl peptidase-IV inhibitors in early development at Sun Pharma

Nov. 26, 2009

Cytopia begins enrollment in phase I/II trial of CYT-387 in myelofibrosis

Nov. 26, 2009

Aleglitazar has no clinically relevant interactions with statins in healthy subjects

Nov. 26, 2009

Phase III data support benefit of mipomersen in homozygous familiar hypercholesterolemia

Nov. 26, 2009

Gilead identifies SCD inhibitors for the treatment of diabetes

Nov. 25, 2009

Shire submits MAA to EMEA for velaglucerase alfa for type 1 Gaucher disease

Nov. 25, 2009

KineMed receives grant from Daiichi Sankyo for clinical Welchol trial in diabetes type 2

Nov. 24, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...